{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T21:01:24Z","timestamp":1780866084776,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"DOI":"10.7759\/cureus.110414","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:57:46Z","timestamp":1780865866000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy"],"prefix":"10.7759","author":[{"given":"Latif","family":"Karahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevtap","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00666","article-title":"Response to (K)RAS(G12C) and EGFR inhibition in a patient with NRAS(G12C)-mutated rectal cancer","volume":"7","author":"M\u00f6hrmann L","year":"2023","unstructured":"M\u00f6hrmann L, Cuberi A, Br\u00fcckmann S, et al.. Response to (K)RAS(G12C) and EGFR inhibition in a patient with NRAS(G12C)-mutated rectal cancer. JCO Precis Oncol. 2023, 7:e2200666. 10.1200\/PO.22.00666","journal-title":"JCO Precis Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis F","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al.. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021, 384:2371-81. 10.1056\/NEJMoa2103695","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen AJ","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, et al.. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023, 401:733-46. 10.1016\/S0140-6736(23)00221-0","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad138","article-title":"Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review","volume":"28","author":"Strickler JH","year":"2023","unstructured":"Strickler JH, Yoshino T, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, Modest DP. Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review. Oncologist. 2023, 28:e981-94. 10.1093\/oncolo\/oyad138","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong DS","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, et al.. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020, 383:1207-17. 10.1056\/NEJMoa1917239","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih MG","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, et al.. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023, 389:2125-39. 10.1056\/NEJMoa2308795","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki Y","year":"2024","unstructured":"Kuboki Y, Fakih M, Strickler J, et al.. Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024, 30:265-70. 10.1038\/s41591-023-02717-6","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1138","article-title":"Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers","volume":"14","author":"Rubinson DA","year":"2024","unstructured":"Rubinson DA, Tanaka N, Fece de la Cruz F, et al.. Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRASG12C cancers. Cancer Discov. 2024, 14:727-36. 10.1158\/2159-8290.CD-23-1138","journal-title":"Cancer Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1285","article-title":"In vitro characterization of sotorasib and other RAS \u2018His95-groove'binders and investigation of resistance mechanisms","volume":"81","author":"Saiki AY","year":"2021","unstructured":"Saiki AY, Mohn D, Li Y, et al.. In vitro characterization of sotorasib and other RAS \u2018His95-groove'binders and investigation of resistance mechanisms. Cancer Res. 2021, 81:1285. 10.1158\/1538-7445.AM2021-1285","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier JJ","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Rep. 2013, 7:223. 10.1186\/1752-1947-7-223","journal-title":"J Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492403-durable-response-to-sotorasib-plus-panitumumab-in-nras-g12c-mutated-microsatellite-instability-high-msi-h-rectal-cancer-refractory-to-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:57:46Z","timestamp":1780865866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492403-durable-response-to-sotorasib-plus-panitumumab-in-nras-g12c-mutated-microsatellite-instability-high-msi-h-rectal-cancer-refractory-to-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.110414","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,7]]}}}